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In Brief
 
Matrix Spacing Controls Adhesion
 
Circulating lymphocytes are floating in a sea of fibrinogen,
fibronectin, and vitronectin, all potential binding partners
for integrins on the cell surface. Somehow adhesion is
turned off until these matrix proteins leak out of the blood
and into tissues at sites of inflammation and injury. Only
then does cleavage by pro-coagulants induce polymeriza-
tion, and the resulting polyvalency, according to Stupack
 
et al. (page 777), results in integrin-mediated adhesion.
ÒIt gives the cell a middle ground, they can explore a situa-
tion without prior activation,Ó says senior author David
Cheresh.
Polymerization does not simply expose new binding
sites for the lymphocytes. Rather it creates a structure with
the correct spacing of binding sites. The clustered integrins
then form functional signaling complexes and activate the
cell.
Spacing rather than average density is the key. Stupack
et al. use as their model a pentavalent coat protein of ade-
novirus, which has presumably evolved for optimum inter-
action with integrins to allow virus uptake. Pentavalent
 
protein distributed at a density of just 125 binding sites/
 
m
 
m
is sufficient for integrin-mediated lymphocyte adherence,
whereas a monovalent version of the protein does not
work at a density of 800 sites/
 
m
 
m.
Adherence alone is sufficient to activate Syk kinase.
Stimulation with antigen also turns on Syk, perhaps allow-
ing fully activated cells to bind even unpolymerized matrix
proteins or proteolyzed fragments. The convergence on
Syk may explain how two stimuli, antigen and extracellu-
lar matrix, cooperate in the activation of immune cells.
 
Sphingolipid Trafficking
 
Lipid transport has been the poor cousin of intracellular
trafficking, so any advance in the field is welcome. On
page 673, Fukasawa et al. characterize a cell line that is de-
fective in the ATP-dependent transport of ceramide from
the endoplasmic reticulum (ER) to the Golgi.
Once ceramide is transported to the Golgi it is con-
verted into sphingomyelin (SM) on the lumenal side, or
glucosylceramide (GlcCer) on the cytosolic side. Fuka-
sawa et al. study this process using the lysenin-resistant
LY-A cell line. Lysenin is a protein from the coelomic
 
fluid of the earthworm 
 
Eisenia foetidia
 
 that binds SM and
lyses the cell, possibly by forming a channel.
The LY-A cell line has low SM but normal levels of cer-
amide and GlcCer. All known enzymes involved in the
metabolism of SM are normal in cell lysates, and SM levels
are restored by treatment with brefeldin A, which merges
 
the ER and the Golgi. The cells are defective in ATP-
dependent transport of a fluorescent derivative of cer-
amide from the ER to the Golgi, whereas trafficking of
proteins remains normal.
The ATP-independent trafficking of ceramide is suffi-
 
cient to maintain production of GlcCer. The energy-depen-
dent step may involve flipping ceramide to the lumenal
side, delivering this topologically-segregated ceramide to
the Golgi, or targeting the trafficking machinery to the
more distal area of the Golgi where SM is made.
 
A Hyaluronan Receptor in the
Lymphatic System
 
Hyaluronan (HA) is a large glycosaminoglycan found in
tissues and body fluids. In vitro it supports cell rolling, and
it can promote cell motility by surrounding the cells and
thus preventing tight cell adhesion. On page 789, Banerji
et al. report the identification of LYVE-1, a new receptor
for HA that is specifically expressed in endothelial cells
lining lymph vessels. LYVE-1 is most similar to CD44, an
HA receptor found on epithelial, mesenchymal, and lym-
phoid cells. The authors speculate that HA may act as a
sandwich between LYVE-1 and CD44, either aiding the
entry of lymphocytes into the lymphatics or promoting
their movement along them. LYVE-1 is important for sev-
eral reasons: it provides an entre into the neglected area
of lymph biology, it is the first useful marker for lymph
vessels, and it may prove important for the spread of can-
cer cells through lymphatics.
 
Controlling Platelet Shape Change
 
The G protein G
 
q
 
 is known to trigger platelet aggregation
and degranulation. Using platelets from a G
 
a
 
q
 
 knockout
mouse, Klages et al. show that the cell shape changes that
accompany normal platelet activation are directed by G
 
12
 
and G
 
13
 
 (page 745).
At the end of the coagulation cascade, thrombin acti-
 
vates platelets to aggregate, degranulate, and change shape,
then thromboxane A
 
2
 
 from activated platelets amplifies
the message. By changing shape from discoid to spheroid
with pseudopodia, platelets expose greater surface area,
and presumably aggregate more easily. The aggregated
platelets form a first line of defense which is strengthened
by the polymerization of coagulation proteins.
 
Klages et al. find that inhibitors of Rho or Rho kinase pre-
vent the shape change and the phosphorylation of myosin
light chain (MLC). A guanine nucleotide exchange factor
(GEF) for Rho is the only known effector for G
 
12
 
 and G
 
13
 
,
so there is a plausible pathway from the G proteins to the
GEF, Rho, Rho kinase, MLC, and finally to a change in
cell shape. MLC phosphorylation, at least in muscle cells,
causes contraction of the actinÐmyosin network. In plate-
lets there may be other cascades that end with actin poly-
merization and changes in the microtubule cytoskeleton.
 
Gene-specific Association with Domains
 
It makes sense that splicing factors would cluster at highly 
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transcribed genes that need them. On page 617, Smith et
al. suggest that the organization of splicing factors is not so
simple. Of two genes with similar amounts of pre-mRNA
in the nucleus, the one with more introns is not associated
with the concentrations of splicing factors termed SC-35
domains.
Nuclear staining with an antibody to SC-35, a spliceo-
some-assembly factor, reveals up to 40 large spots and nu-
merous smaller speckles. Smith et al. define the large spots
as SC-35 domains (sometimes also referred to as inter-
chromatin granule clusters). The Lawrence group has pre-
viously noted the association of several highly expressed
genes with these domains. In this report they note that the
myosin heavy chain (MyHC) gene follows this pattern, but
the dystrophin gene does not.
Dystrophin transcription is initiated less frequently than
MyHC transcription, but it takes far longer to complete
thanks to the size of the gene. Therefore, the total amount
of pre-mRNA accumulated in the nucleus is approxi-
mately equal for the two genes. Dystrophin pre-mRNA is
distributed in a large patch along the length of the gene,
presumably as a ÒtreeÓ of nascent transcripts. The patch of
MyHC is of a similar size but tails away from the gene in a
ÒtrackÓ that may be involved in export from the nucleus.
How can we explain the difference in domain associa-
tion? The dystrophin/MyHC difference might arise from
the variation in track vs. tree organization or transcription
initiation rate. But of four other genes that share similar
sizes, complexity, and moderate expression levels, two are
associated with the domains and two are not. There is no
gene sequestration (at least for dystrophin) in the dorsal
and peripheral regions of the nucleus where SC-35 do-
mains do not form.
Two classes of mechanism might explain domain forma-
tion at specific loci: an active mechanism directed by spe-
cific DNA or RNA sequences, or a more passive agglom-
eration of splicing factors from one or several active genes.
Smith et al. postulate that some highly active genes may
nucleate the formation of domains, with other active genes
in the ÒneighborhoodÓ then associating with the domains.
Swapping gene locations by targeted integrations should
provide some answers.
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